**Hydrosalpinx – salpingostomy, salpingectomy or tubal occlusion**

Dr. Ka Ying Bonnie Nga, b

Professor Ying Cheonga, b

Guest Editor: Professor T.C. Li

a Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK

b Department of Obstetrics and Gynaecology, Princess Anne Hospital, Level F, Coxford Road, Southampton, SO16 5YA, UK

Corresponding author: Ka Ying Bonnie Ng, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK, bonnie.ng@soton.ac.uk

**Abstract**

Tubal factors account for around 25% of cases of infertility and the most severe manifestation of tubal disease is hydrosalpinx, accounting for 10-30% of tubal diseases. Hydrosalpinx is a distension or dilatation of the Fallopian tube in the presence of a distal tubal occlusion, and the most common cause is pelvic inflammatory disease. Women with hydrosalpinges have lower implantation and pregnancy rates in assisted reproductive technology (ART), due to a combination of mechanical and chemical factors thought to disrupt the endometrial environment. Current guidance is removal the tube by salpingectomy (preferably laparoscopically) prior to IVF treatment. Salpingostomy, or distal tubal plastic surgery in the management of hydrosalpinx is an alternative for women desiring natural conception, although ectopic pregnancy rates as high as 10% have been reported. Proximal tubal occlusion with Essure ® devices placed hysteroscopically can be considered especially in cases of distorted pelvic anatomy or pelvic adhesions making abdominal surgery complex. However, lower clinical pregnancy and live birth rates have been reported with the use of these devices prior to IVF. In the review, we discuss salpingostomy, salpingectomy and hysteroscopic tubal occlusion as possible management options for the reproductive women with hydrosalpinx.

**Keywords:** hydrosalpinx, salpingectomy, salpingostomy, tubal occlusion, IVF, natural conception

**Hydrosalpinx**

Tubal factors account for around 25% of cases of infertility and the most severe manifestation of tubal disease is hydrosalpinx. Hydrosalpinx, derived from Greek, meaning “water tube” is a distension or dilatation of the Fallopian tube in the presence of a distal tubal occlusion, and the disease may affect the proximal, distal or entire tube 1,2. There are many different causes including pelvic inflammatory diseases (PID), endometriosis, appendicitis or previous pelvic or abdominal surgery 3. PID is the most common cause, usually resulting from prior sexually transmitted disease such as *Chlamydia trachomatis* or *Neisseria Gonorrhoea*, resulting in severe inflammatory processes, obstructing the distal end of the tube 3. The non functioning hydrosalpinx fluid occurs as a result of inflammatory processes and natural transitional mucosal production.

The prevalence of hydrosalpinges in patients suffering from tubal disease is common; 10-13% are diagnosed on ultrasound 4,5 (Figure 1) and up to 30% are diagnosed by hysterosalpingography, laparoscopy, or during open surgery 6-8.

**Effects of hydrosalpinx on reproductive outcomes**

It is now accepted that fluid within a hydrosalpinx plays a causative role in reducing pregnancy rates in assisted reproductive technology (ART); the success of ART for women with hydrosalpinx tubal disease is reduced by 50% compared with women who do not have a hydrosalpinx 9 1011. Anderson et al. showed that when hydrosalpinx was present in patients undergoing IVF/ET, there was a lower implantation rate (2.9% compared to 10% in the group with no hydrosalpinx) and a lower pregnancy rate (22% compared to 36% in the group with no hydrosalpinx), despite a comparable number of aspirated oocytes and embryos transferred during the IVF cycle5. They also have higher rates of ectopic pregnancy and miscarriages2,10.

There are many theories on why women with hydrosalpinges have impaired reproductive outcomes, although the exact cause remains unknown. Mechanical and chemical factors and suboptimal endometrial receptivity have been shown to adversely affect IVF outcomes. It has been thought that leakage of fluid in the uterine cavity disturbs the endometrial receptivity to the developing embryo 5. Although not fully understood, several candidate genes and proteins involved in implantation may have altered patterns of expression when hydrosalpinges are present. The unfavourable intrauterine environment may result from toxic substances draining into the cavity and diluting endometrial secretions 6,9,12. Lavage of the endometrial cavity is consistent with chronic vaginal discharge observed in women with hydrosalpinges13. One study showed that none of the women with hydrosalpinx who had uterine cavity distension in the luteal phase had achieved ongoing intrauterine pregnancy after IVF treatment 14.

**Management of hydrosalpinx**

The UK’s National Institute of Health and Clinical Excellence (NICE) suggest the management of hydrosalpinx by laparoscopic Salpingectomy prior to commencement of IVF15. A further Cochrane review showed that laparoscopic salpingectomy or tubal occlusion before IVF improves the chances of IVF success16. Here we discuss salpingostomy, salpingectomy and proximal tubal occlusion (laparoscopic and hysteroscopic approaches) as possible management options.

***Salpingostomy***

Salpingostomy is distal tubal plastic surgery to manage hydrosalpinx using scissors, electrosurgery or laser17,18, with the aim of conserving the Fallopian tubes and allowing the women to attempt natural conception. During surgery, the distal tube is incised and opened in the avascular area, and the newly created ostium is sutured back to the mesosalpinx. Great care is needed to minimise the creation of raw surfaces. However, since the increased use of IVF/ICSI treatment, sterilising surgery (salpingectomy and tubal occlusion) has been shown to double the chance of IVF success6,14,16, and is now being performed in preference to ensure that the hydrosalpingeal fluid does not contact or disrupt the endometrial environment.

Sterilising surgery has a major disadvantage in that a patient who has bilateral disease will rely on IVF/ICSI treatment to achieve a future pregnancy. A systematic review of 22 studies (including 2810 patients) showed that women who had undergone salpingostomy for hydrosalpinx had a spontaneous pregnancy rate of 27%, cumulative clinical pregnancy rate of 25.5% at 24 months after salpingostomy, and a live birth rate of 25%, suggesting that it is an effective alternative treatment strategy to sterilising tubal procedures19. However, there is a high risk of ectopic pregnancy at 10% and further studies are needed to identify the subpopulation that would benefit the most from tube conserving surgery, with reasonable chances of subsequent natural conception19. For example, in older women or those with substantial damage to tubes secondary to severe hydrosalpinges, proceeding directly to salpingectomy and IVF treatment may be most appropriate, rather than salpingostomy. There also needs to be consideration into the necessary expertise for reconstructive tubal surgery.

Winston et al. showed that the degree of tubal damage, determined by the degree of mucosal damage and tubal fibrosis, presence of isthmic disease and the quality of tubal and ovarian adhesions affects prognosis20. Amongst those with stage one disease, 39% had successful live births after primary salpingostomy20. For thin walled hydrosalpinges with good mucosa, surrounded by few or flimsy adhesions, excellent outcomes have been reported after tubal reconstructive surgery with more than half of the patients achieving an intrauterine pregnancy21.Conversely, thick walled hydrosalpinges with fibrosis of the wall have poor prognosis. Recurrence rate of hydrosalpinx after salpingostomy has been reported to be as high as 70% in the poor prognostic group22.

There may be a role of salpingoscopy or tubal endoscopy in excluding mucosal adhesions and predicting individuals with more than 50% intrauterine and less than 5% tubal pregnancy rate following reconstructive surgery23,24. Salpingoscopy allows direct visualisation of the ampullary mucosa and intraluminal adhesions and may allow better selection of patients most suitable for functional surgery.

***Salpingectomy***

Current data strongly supports laparoscopic salpingectomy in the management of hydrosalpinx in terms of clinical and ongoing pregnancy rates, and NICE recommends salpingectomy, preferably by laparoscopy before IVF treatment15. Johnson et al. showed that the ongoing clinical pregnancy rates in the intervention group were 31% versus 17.6% in the control group (odds ratio [OR] 2.2, 95% confidence interval [CI] 1.26-3.82)16.

In salpingectomy, chronically infected tissue is removed and thus limits the chances of subsequent abscess formation or torsion, as well as improved access to the ovaries during egg retrieval in IVF25. However, laparoscopy remains an invasive procedure, which in the presence of dense adhesions, may be very difficult. With laparoscopy, there are risks of damage to major organs or vessels, such as those with previous abdomino-pelvic surgery, severe endometriosis, and inflammatory bowel disease.

Salpingectomy also carries an increased risk of interstitial pregnancy (IP) (pregnancy within the part of the Fallopian tube that is located in the uterine wall and connects with the remainder of the tube to the endometrial cavity) in cases where the transection of the Fallopian tube is at a site too close to the cornua. Wang et al. identified 43 cases of IP, of which 71% had undergone bilateral salpingectomy prior to IVF26. A corneal suture placed at the time of laparoscopic salpingectomy has been shown to reduce the risk of IP, increasing the rate of intrauterine pregnancy, ongoing pregnancy and live birth rates compared to those without placement of a corneal suture27.

Some studies have shown impaired ovarian blood flow following salpingectomy, which adversely impacts on response to ovarian stimulation 28,29. A meta-analysis of 25 studies showed that the gonadotropin dose required for stimulation in IVF was increased and the number of oocytes retrieved was decreased in the salpingectomy group compared to the control group30. Operating close to the Fallopian tube and away from the ovarian vessels and suspensory ligament is recommended to minimise devascularisation of the ovary (Figure 2).

***Proximal tubal occlusion***

Proximal tubal occlusion is considered as an alternative management option, especially in cases of distorted pelvic anatomy in those with severe pelvic adhesions. Studies have reported comparable implantation and pregnancy rates in women who had undergone tubal occlusion, salpingectomy and salpingostomy31,32.

The procedure is less invasive, easier and quicker to perform. The advantages are that the retrograde flow of the hydrosalpingeal fluid, thought to contribute to a perturbed uterine environment is eliminated and the integrity of the ovarian blood supply is maintained. However, tubal occlusion may be associated with ongoing pelvic pain secondary to the pressure and presence of the diseased tube, and risks of adnexal torsion, and subsequent need for adnexal surgery33.

In laparoscopic tubal occlusion, the medial end of the tube can be cauterised and divided or occluded with a clip (Filshie Clip or Hulka-Clemens clip). The Filshie Clip is a titanium-silicone clip that uses the pressure exerted by the applicator to close the clip. The Hulka-Clemens clip is plastic with a gold plated stainless steel spring, and the spring mechanism holds the clip closed when applied to the tube. However, there are reported cases of clip migration and chronic pelvic pain post procedure34.

Essure ® and Adiana ® are devices described for hysteroscopic tubal occlusion, but only the former has been used so far in the management of hydrosalpinx. Essure ® has been widely used for hysteroscopy tubal sterilisation35. It is a microinsert, 4cm in length and 2mm in diameter when expanded. Polyethylene terephthalate fibers, which run through the inner coil of the Essure ® device cause a tissue reaction and resultant tubal occlusion when inserted.

A systematic review of 11 studies (115 women) who had received Essure ®, showed successful placement in 96.5% and tubal occlusion in 98.1%36. With subsequent IVF, a reasonable pregnancy rate of 38.6% and live birth rate of 27.9% were achieved, and authors concluded that Essure ® is an effective option for management of hydrosalpinx in women before IVF, where operative treatment options are limited by pelvic adhesions36. However, a two centre RCT (involving 85 women) following from this showed that prior to IVF/ICSI, hysteroscopic tubal occlusion is inferior to laparoscopic salpingectomy; the ongoing pregnancy rates per patient following proximal tubal occlusion by intratubal devices was 26.2% compared with 55.8% following laparoscopic salpingectomy (p=0.008)37. Furthermore, a systematic review of over 3000 patients showed that management of hydrosalpinx by hysteroscopic placement of Essure ® devices prior to IVF produces lower clinical pregnancy and live birth rates compared to laparoscopic salpingectomy and laparoscopic proximal tubal occlusion. 38 We do not therefore recommend Essure® as a form of treatment for hydrosalpinges.

**Summary**

The detrimental effect of hydrosalpinx on the uterine milieu during the implantation window has been well described. Current guidance supports the use of salpingectomy or proximal tubal occlusion in women with hydrosalpinx prior to IVF or ICSI as there are higher chances of successful treatment and improved pregnancy rates. However, there still remains a role for salpingostomy in the treatment of hydrosalpinx in a subgroup of women, who are reasonable candidates for a trial of natural conception. Individualised care, taking into consideration the women’s risk profile and desires are required to help her make an informed decision, considering the full range of treatment options.

**Practice points**

* Appropriate management of hydrosalpinx in a women with reproductive potential needs to take into consideration the risk profile, the women’s desires and the local expertise of reproductive specialists.
* The detrimental impact of hydrosalpinx prior to assisted reproductive technology, such as IVF has been well documented and thus salpingectomy is recommended to optimise chances of successful implantation and pregnancy prior to IVF.
* Salpingostomy may have a role in a specific cohort of women who have reasonable chances of spontaneous conception.

**Research agenda**

* Research into how the presence of hydrosalpinx can affect the intrauterine environment would be useful. This would further our understanding of the environment surrounding the embryo during implantation and how disruption to this physiological control may lead to reproductive failures.
* Research into how the hydrosalpinx fluid is toxic to the developing embryo can be studied.
* The role of selective salpingostomy or salpingectomy in the management of hydrosalpinx dependent on the size of the distension has not been explored.

**Acknowledgements**

We would like to acknowledge Dr Maulik S Patel who has provided permission to use the image taken from Radiopaedia.org, rID: 18262 for Figure 1. We would also like to thank Dr Roel Mingels for his support with figures in this paper.

**Conflicts of interest**

The authors have no conflicts of interest

**Figure Legends**

Figure 1- Left hydrosalpinx seen on ultrasound.

Figure 2- Salpingectomy in management of hydrosalpinx. Operating close to the Fallopian tube and away from the ovarian vessels and suspensory ligament is recommended to minimise devascularisation of the ovary. In cases of impaired ovarian blood flow following salpingectomy, response to ovarian stimulation in IVF can be poor.

**References**

\*Important references

1. Aboulghar MA, Mansour RT, Serour GI. Controversies in the modern management of hydrosalpinx. *Hum Reprod Update* 1998;4(6):882-90.

2. Strandell A. The influence of hydrosalpinx on IVF and embryo transfer: a review. *Hum Reprod Update* 2000;6(4):387-95.

3. Puttemans PJ, Brosens IA. Salpingectomy improves in-vitro fertilization outcome in patients with a hydrosalpinx: blind victimization of the fallopian tube? *Hum Reprod* 1996;11(10):2079-81.

4. Katz E, Akman MA, Damewood MD, et al. Deleterious effect of the presence of hydrosalpinx on implantation and pregnancy rates with in vitro fertilization. *Fertil Steril* 1996;66(1):122-5.

5. Andersen AN, Yue Z, Meng FJ, et al. Low implantation rate after in-vitro fertilization in patients with hydrosalpinges diagnosed by ultrasonography. *Hum Reprod* 1994;9(10):1935-8.

6. Strandell A, Waldenstrom U, Nilsson L, et al. Hydrosalpinx reduces in-vitro fertilization/embryo transfer pregnancy rates. *Hum Reprod* 1994;9(5):861-3.

7. Blazar AS, Hogan JW, Seifer DB, et al. The impact of hydrosalpinx on successful pregnancy in tubal factor infertility treated by in vitro fertilization. *Fertility & Sterility* 1997;67(3):517-20.

8. Lass A. What effect does hydrosalpinx have on assisted reproduction? What is the preferred treatment for hydrosalpines? The ovary's perspective. *Hum Reprod* 1999;14(7):1674-7.

9. Vandromme J, Chasse E, Lejeune B, et al. Hydrosalpinges in in-vitro fertilization: an unfavourable prognostic feature. *Hum Reprod* 1995;10(3):576-9.

10. Zeyneloglu HB, Arici A, Olive DL. Adverse effects of hydrosalpinx on pregnancy rates after in vitro fertilization-embryo transfer. *Fertil Steril* 1998;70(3):492-9.

11. Camus E, Poncelet C, Goffinet F, et al. Pregnancy rates after in-vitro fertilization in cases of tubal infertility with and without hydrosalpinx: a meta-analysis of published comparative studies. *Hum Reprod* 1999;14(5):1243-9.

12. Bildirici I, Bukulmez O, Ensari A, et al. A prospective evaluation of the effect of salpingectomy on endometrial receptivity in cases of women with communicating hydrosalpinges. *Hum Reprod* 2001;16(11):2422-6.

13. Watermeyer SR, Bhal K. Chronic vaginal discharge secondary to a hydrosalpinx. *J Obstet Gynaecol* 2002;22(3):324.

14. Akman MA, Erden HF, Bahceci M. Endometrial fluid visualized through ultrasonography during ovarian stimulation in IVF cycles impairs the outcome in tubal factor, but not PCOS, patients. *Hum Reprod* 2005;20(4):906-9.

15. NICE Clinical Guideline. *Fertility: assessment and treatment for people with fertility problems.* <https://www.nice.org.uk/guidance/cg156/evidence/full-guideline-pdf-188539453> (accessed 26.11.18).

16. Johnson N, van Voorst S, Sowter MC, et al. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation. *Cochrane Database Syst Rev* 2010(1):CD002125.

17. Gomel V, Wang I. Laparoscopic surgery for infertility therapy. *Curr Opin Obstet Gynecol* 1994;6(2):141-8.

18. Hamilton CJ, Evers JL, Hoogland HJ. Ovulatory disorders and inflammatory adnexal damage: a neglected cause of the failure of fertility microsurgery. *Br J Obstet Gynaecol* 1986;93(3):282-4.

19. Chu J, Harb HM, Gallos ID, et al. Salpingostomy in the treatment of hydrosalpinx: a systematic review and meta-analysis. *Hum Reprod* 2015;30(8):1882-95.

20. Winston RM, Margara RA. Microsurgical salpingostomy is not an obsolete procedure. *Br J Obstet Gynaecol* 1991;98(7):637-42.

21. Boer-Meisel ME, te Velde ER, Habbema JD, et al. Predicting the pregnancy outcome in patients treated for hydrosalpinx: a prospective study. *Fertil Steril* 1986;45(1):23-9.

22. Bayrak A, Harp D, Saadat P, et al. Recurrence of hydrosalpinges after cuff neosalpingostomy in a poor prognosis population. *J Assist Reprod Genet* 2006;23(6):285-8.

23. Dechaud H, Daures JP, Hedon B. Prospective evaluation of falloposcopy. *Hum Reprod* 1998;13(7):1815-8.

24. Marana R, Catalano GF, Muzii L, et al. The prognostic role of salpingoscopy in laparoscopic tubal surgery. *Hum Reprod* 1999;14(12):2991-5.

25. Sharif K, Kaufmann S, Sharma V. Heterotopic pregnancy obtained after in-vitro fertilization and embryo transfer following bilateral total salpingectomy: case report. *Hum Reprod* 1994;9(10):1966-7.

26. Wang J, Huang D, Lin X, et al. Incidence of Interstitial Pregnancy After In Vitro Fertilization/Embryo Transfer and the Outcome of a Consecutive Series of 38 Cases Managed by Laparoscopic Cornuostomy or Cornual Repair. *J Minim Invasive Gynecol* 2016;23(5):739-47.

27. Chen J, Huang D, Shi L, et al. Cornual Suture at the Time of Laparoscopic Salpingectomy Reduces the Incidence of Interstitial Pregnancy after In Vitro Fertilization. *J Minim Invasive Gynecol* 2018;25(6):1080-87.

28. Gelbaya TA, Nardo LG, Fitzgerald CT, et al. Ovarian response to gonadotropins after laparoscopic salpingectomy or the division of fallopian tubes for hydrosalpinges. *Fertil Steril* 2006;85(5):1464-8.

29. Orvieto R, Saar-Ryss B, Morgante G, et al. Does salpingectomy affect the ipsilateral ovarian response to gonadotropin during in vitro fertilization-embryo transfer cycles? *Fertil Steril* 2011;95(5):1842-4.

30. Fan M, Ma L. Effect of salpingectomy on ovarian response to hyperstimulation during in vitro fertilization: a meta-analysis. *Fertil Steril* 2016;106(2):322-29 e9.

31. Murray DL, Sagoskin AW, Widra EA, et al. The adverse effect of hydrosalpinges on in vitro fertilization pregnancy rates and the benefit of surgical correction. *Fertil Steril* 1998;69(1):41-5.

32. Kontoravdis A, Makrakis E, Pantos K, et al. Proximal tubal occlusion and salpingectomy result in similar improvement in in vitro fertilization outcome in patients with hydrosalpinx. *Fertil Steril* 2006;86(6):1642-9.

33. LaCombe J, Ginsburg F. Adnexal torsion in a patient with hydrosalpinx who underwent tubal occlusion before in vitro fertilization. *Fertil Steril* 2003;79(2):437-8.

34. Kalu E, Croucher C, Chandra R. Migrating Filshie clip: an unmentioned complication of female sterilisation. *J Fam Plann Reprod Health Care* 2006;32(3):188-9.

35. Ouzounelli M, Reaven NL. Essure hysteroscopic sterilization versus interval laparoscopic bilateral tubal ligation: a comparative effectiveness review. *J Minim Invasive Gynecol* 2015;22(3):342-52.

36. Arora P, Arora RS, Cahill D. Essure((R)) for management of hydrosalpinx prior to in vitro fertilisation-a systematic review and pooled analysis. *BJOG* 2014;121(5):527-36.

37. Dreyer K, Lier MC, Emanuel MH, et al. Hysteroscopic proximal tubal occlusion versus laparoscopic salpingectomy as a treatment for hydrosalpinges prior to IVF or ICSI: an RCT. *Hum Reprod* 2016;31(9):2005-16.

38. Xu B, Zhang Q, Zhao J, et al. Pregnancy outcome of in vitro fertilization after Essure and laparoscopic management of hydrosalpinx: a systematic review and meta-analysis. *Fertil Steril* 2017;108(1):84-95 e5.